Claimed effect · Noopept (omberacetam)

Does Noopept (omberacetam) help with cognitive impairment after brain injury or stroke?

D
Grade D — no human evidence1 Russian comparative trial (vs piracetam) · effect size: not measurable
Short answerNo human evidence. As of 10 September 2026, only 1 Russian comparative trial (vs piracetam) exists for Noopept (omberacetam) for cognitive impairment after brain injury or stroke. The basis of the Russian registration. Published in Russian in 2008 and in translation in 2009; the indexed record has no abstract, so the size, blinding and outcome measures cannot be assessed from the international literature. Not replicated.

What the studies show

The basis of the Russian registration. Published in Russian in 2008 and in translation in 2009; the indexed record has no abstract, so the size, blinding and outcome measures cannot be assessed from the international literature. Not replicated.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

  1. 1
  2. 2

In context

Noopept is a synthetic molecule built from the dipeptide proline-glycine, developed at the Zakusov Institute in Moscow and registered in Russia as a nootropic for mild cognitive impairment after brain injury or stroke. Outside Russia it is not approved anywhere. The human evidence is a single Russian comparison against piracetam in patients with vascular or traumatic cognitive impairment; its English translation carries no abstract in PubMed, and no independent group has replicated it. The claims made for it in healthy people — focus, memory, learning — have never been tested in a controlled trial.

Noopept (omberacetam) is not approved (outside russia). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Noopept (omberacetam) proven to help with cognitive impairment after brain injury or stroke?
No. There is no human evidence for it (1 Russian comparative trial (vs piracetam)); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
The basis of the Russian registration. Published in Russian in 2008 and in translation in 2009; the indexed record has no abstract, so the size, blinding and outcome measures cannot be assessed from the international literature. Not replicated.
Is Noopept (omberacetam) approved for this?
No. Noopept (omberacetam) is not approved (outside Russia); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Noopept (omberacetam)

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →